Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1

BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017. The event will bring together leading expert allergists to discuss the emerging treatment landscape in peanut allergy.

Topics at Aimmune’s Investor Symposium will include the practice of allergy in the community setting, considerations for developing approved treatment options for food allergy, and treatment expectations in the peanut allergy community. The Aimmune management team will also review progress in the Phase 3 clinical development program for AR101, discuss Phase 2 data for and experience with AR101, and review anticipated upcoming milestones. AR101 is Aimmune’s investigational oral biologic desensitization therapy for peanut allergy, which is currently in Phase 3 clinical development. A question and answer session will follow the formal presentations.

Guest Physician Presenters

Ellen R. Sher, MD, is an allergist and immunologist of Allergy Partners of New Jersey, P.C., Section Chief of Allergy and Immunology at Monmouth Medical Center, and a Clinical Assistant Professor of Medicine at Drexel Medical School. Dr. Sher received her medical degree from Georgetown University and completed her residency at Thomas Jefferson University Hospital in Philadelphia followed by a fellowship in pulmonary medicine. She then completed a fellowship in Allergy & Immunology at the National Jewish Center for Immunology and Respiratory Medicine. Dr. Sher is a past president of the NJ Allergy, Asthma, & Immunology Society and current principal investigator of Atlantic Research Center, where she has participated in over 150 clinical research studies. Dr. Sher currently serves on several national committees for The American Academy of Allergy, Asthma & Immunology and The American College of Allergy, Asthma & Immunology.

Stephen A. Tilles, MD, is Clinical Professor at the University of Washington, Executive Director of ASTHMA Inc.Clinical Research Center, and Physician Partner at the Northwest Asthma and Allergy Center. Dr. Tilles received his medical degree from the University of California at San Diego. He completed his internship and residency in internal medicine at the Oregon Health Sciences University, and his allergy and immunology fellowship at the National Jewish Center for Immunology and Respiratory Medicine. He was previously an Assistant Professor of Medicine and Pediatrics and Director of the Allergy and Asthma Clinic at the Oregon Health Sciences University and has served as principal investigator for more than 140 clinical research studies. Dr. Tilles is a past president of the Western Society of Asthma, Allergy and Immunology and the Oregon Society of Allergy, Asthma, and Immunology. He is currently Immediate Past-President of the American College of Allergy, Asthma, and Immunology.

Event and Webcast Details

The Investor Symposium will be held on Friday, December 1, 2017, from 8:00-10:30 a.m. Eastern Time in New York City. Analysts and investors may register for the event by contacting LifeSci Advisors, LLC, at mac@lifesciadvisors.com. A live webcast of the event will be available and may be accessed in the Investor Relations section of Aimmune’s website at www.aimmune.com under the Events page. A replay will be available for at least 30 days.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, is developing treatments for life-threatening food allergies. Aimmune’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Source: Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao,650-351-6479
syao@aimmune.com